All News

Our SLR on pathogenesis of SARS-CoV-2 Main findings: TH1 cytokines and IL-6 associated w/ severe COVID19 and fatal outcomes. ⬆️ classical blood monocytes and polyfunctional T cells. Impaired IFN response associated w/ poor outcomes. #POS0052 @Rheumnow #EULAR2021 @alessia_alunno https://t.co/PGph5IRBkX
Aurelie Najm AurelieRheumo ( View Tweet)
Each line is a different country's JAK inhibitor for RA registry, looking at drug stopped for adverse events. Why all the variation? (Until we sort that out, we'll struggle to assess JAKi post-marketing safety...) @k_lauper's JAK-pot study POS0093 #EULAR2021 @RheumNow https://t.co/YykoG7LlEw
David Liew drdavidliew ( View Tweet)
German SpA Inception Cohort analyses: TNFi assc w/ ⬇️ sacroiliitis and spinal dz progression in axSpA pts, but the effect is evident starting between 2 and 4 years post tx induction. #EULAR2021 Abstracts #OP0137 & #OP0139 @RheumNow https://t.co/uR9rug6zqI https://t.co/xF3wcxm4cf https://t.co/lEsUvOSJ6K

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

@jeffsparks wahooo! Congrats on the #EULAR2021 clinical science award recognition!

Dr. Rachel Tate uptoTate ( View Tweet)

#EULAR2021 #EULAR21 #eular #spondyloarthritis I have always thought we named nr-axSPA wrongly - Tends to trivialise its gravity and importance Shouldn’t it be our goal to diagnose all SpA at the nr-axSPA stage @deodhara @NigilHaroon https://t.co/zwKI1o9WcO
EnvisionRheumat ERheumat ( View Tweet)
Patient profiles have changed in clinical trials of PsA #EULAR2021 https://t.co/6l2RfOPkSq
Dr Irwin Lim _connectedcare ( View Tweet)
#EULAR2021: AxSpA patients with greater patient-reported pain and spinal pain relative to axPsA patients among real-world patients in CorEVitas' Psa/Spa observational Registry per Dr. Mease's oral abstract presentation. @RheumNow https://t.co/YEdhd7x6cb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 - Key points from Dr. Mease's oral abstract: ⭐️AxSpA pts were younger & more likely to be male & have a hx of uveitis & IBD ⭐️AxSpA pts had less exposure to prior therapies relative to axPsA pts ⭐️AxSpA assoc w/ > spinal pain regardless of b/tsDMARD status @Rheumnow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

#EULAR2021: AxSpA patients more likely to experience IBD and uveitis whereas axPsA more likely to experience dactylitis and enthesitis per Dr. Philip Mease's study among real-world patients in CorEVitas' Psa/Spa Registry. @RheumNow https://t.co/g2m5fylFJj
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: SpA pts w/ predominant axial phenotype tended to be HLAB27+ & have uveitis whereas those w/ predom peripheral phenotype tended to have arthritis, dactylitis, or psoriasis & fit a clinical dx of axSpA & psSpa (incl psA) respectively per this observat study. @RheumNow https://t.co/E5UTbc6Sqb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 bDMARD and TNF-i naive patients w/ r-axSpA without evidence of objective inflammation (normal CRP & MRI ) showed ASA40 response w/ ixekizumab @RheumNow https://t.co/5KT8A81auq
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#OP0089 Do you know the pain catastrophizing score #PCS ? Cross-sectional study of 1199 #RA, #PsA & #ax-SpA patients: Low PCS were more often in remission as high PCS in RA & ax-SpA. PCS was associated with remission rates in RA and ax-SpA, but not in PsA #EULAR2021 @RheumNow https://t.co/MYiLmPPbDN
Paul Studenic Stiddyo ( View Tweet)
#EULAR2021: "I am an advocate for smart T2T, not a mathematical T2T approach." - Dr. Filip van den Bosch @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

#EULAR2021: In India, some of the JAKi are costing less than $30/mo per a EULAR participant! Dr. Filip van den Bosch does not recommend using tofacitinib as a diagnostic tool for SpA over NSAIDs even if it is so cheap. @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

#EULAR2021: Reduced likelihood of reaching disease remission in patients with RA or PsA who have concomitant depression and anxiety per prospective NOR-DMARD study. Social state and mental health factors play an important role in noresponse in T2T approach. @RheumNow https://t.co/Vl0Xkz2SNF
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021: Dr. Filip van den Bosch recommends the "DEER" treatment approach for SpA: Dedicated Empathic and Educated Rheumatologist! @RheumNow https://t.co/W0jbGXk7q8
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Prof. Alten outlined the value of patient-reported outcomes for clinical practice! How do you collect patient-reported outcomes - PRO - in your rheumatology clinic? #EULAR2021 @RheumNow

Paul Studenic Stiddyo ( View Tweet)

Skin fibroblasts in #CRPS: Immunohistological staining of NT3 showed higher expression in the affected vs. not affected side. Increasing NT3 expression <> pain increase. -->dysregulated communication of #fibroblasts with the sensory nerve fibers. #OP0085 #EULAR2021 @RheumNow

Paul Studenic Stiddyo ( View Tweet)

#OP0049 corevitas observational registry: ax-SpA patients showed younger age, more males, greater spinal pain, more exposure to cs- or bDMARD but similar fatigue and work impairment compared to ax-PsA #EULAR2021 @RheumNow

Paul Studenic Stiddyo ( View Tweet)

×